Published in Gene Therapy Weekly, November 10th, 2005
According to a study from the United States, "Activating K-Ras mutations are found in approximately 90% of pancreatic carcinomas and may contribute to the poor prognosis of these tumors. Because radiotherapy is frequently used in pancreatic cancer treatment, we assessed the contribution of oncogenic K-Ras signaling to pancreatic cancer radiosensitivity."
"Seven human pancreatic carcinoma lines with activated K-Ras and 2 cell lines with wild-type Ras were used to examine clonogenic cell survival after Ras inhibition. Ras inhibition was accomplished...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.